DocuSign expands leadership team with newly created roles across strategy, marketing & growth DocuSign expands leadership team with newly created roles across strategy, marketing & growth PR Newswire SAN FRANCISCO, Jan. 30, 2023 Seasoned marketing and operational leaders from...

DocuSign, Inc. (NASDAQ:DOCU Get Rating) Director Daniel D. Springer sold 147,008 shares of DocuSign stock in a transaction dated Thursday, January 19th. The shares were sold at an average price of $55.08, for a total value of $8,097,200.64. Following the completion of the transaction, the ...

DocuSign, Inc. (NASDAQ:DOCU Get Rating) Director Daniel D. Springer sold 147,009 shares of the stock in a transaction on Tuesday, January 17th. The stock was sold at an average price of $58.48, for a total value of $8,597,086.32. Following the sale, the director now owns 1,524,335 shares of the ...

Thinking about trading options or stock in Biomarin Pharmaceutical, Docusign, Apple, MicroStrategy, or Allstate Corp? Thinking about trading options or stock in Biomarin Pharmaceutical, Docusign, Apple, MicroStrategy, or Allstate Corp? PR Newswire NEW YORK, Jan. 5, 2023 NEW YORK, Jan. 5, 2023...

DocuSign (NASDAQ:DOCU Get Rating) had its price target upped by Citigroup from $59.00 to $72.00 in a research report report published on Monday morning, Benzinga reports. They currently have a buy rating on the stock. Several other equities research analysts have also weighed in on the company. ...